Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Prevention and risk

Topic: Amyloid, tau and blood-test diagnosis

Introduction It is challenging at baseline to predict when and which individuals who meet criteria for mild cognitive impairment (MCI) will ultimately progress to Alzheimer's disease (AD) dementia. Methods A deep learning method is developed and validated based on magnetic resonance imaging scans of 2146 subjects (803 for training and 1343 for validation) to predict MCI subjects' progression to AD dementia in a time-to-event analysis setting. Results The deep-learning time-to-event model predicted individual subjects' progression to AD dementia with a concordance index of 0.762 on 439 Alzheimer's Disease Neuroimaging Initiative testing MCI subjects with follow-up duration from 6 to 78 months (quartiles: [24, 42, 54]) and a concordance index of 0.781 on 40 Australian Imaging Biomarkers and Lifestyle Study of Aging testing MCI subjects with follow-up duration from 18 to 54 months (quartiles: [18, 36, 54]). The predicted progression risk also clustered individual subjects into subgroups with significant differences in their progression time to AD dementia (P Discussion Our method provides a cost effective and accurate means for prognosis and potentially to facilitate enrollment in clinical trials with individuals likely to progress within a specific temporal period.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Li, H., Habes, M., Wolk, D. A., & Fan, Y. (2019). A deep learning model for early prediction of Alzheimer's disease dementia based on hippocampal magnetic resonance imaging data. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1016/j.jalz.2019.02.007

Vancouver

Li H, Habes M, Wolk DA, Fan Y. A deep learning model for early prediction of Alzheimer's disease dementia based on hippocampal magnetic resonance imaging data. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2019. doi:10.1016/j.jalz.2019.02.007. PMID: 31201098.

BibTeX

@article{li2019-31201098,
  author  = {Li, H. and Habes, M. and Wolk, D. A. and Fan, Y.},
  title   = {{A deep learning model for early prediction of Alzheimer's disease dementia based on hippocampal magnetic resonance imaging data}},
  journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
  year    = {2019},
  doi     = {10.1016/j.jalz.2019.02.007},
  pmid    = {31201098},
  url     = {https://doi.org/10.1016/j.jalz.2019.02.007}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This deep learning model predicted progression from mild cognitive impairment to Alzheimer's dementia from hippocampal MRI data, with a concordance index of 0.762 in one testing group and 0.781 in another. It is a prognostic tool for identifying likely progressors, not a treatment or cure.

Study details

How this study scored 56/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 5 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 2 of 6; Still being cited 3 of 4; Senior author's track record left out, no data; Institution's track record 2 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 54 of the 96 points it could be judged on, which is 56 of 100. Total 56 of 100.54 of the 96 points we could judge = 56 of 100

Published in a leading specialty journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 54 of the 96 points we could judge it on, which is 56 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2019 — within 10 year(s) of the newest study here
Sample size 3 / 4 2,146 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 269 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 29.9 citations a year over 9 year(s) since 2019
Impact for its field and year 5 / 6 Cited 22.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 7 other studies in this library
Still being cited 3 / 4 Cited 104 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record 2 / 3 University of Pennsylvania: institution h-index 1,859 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 31201098)
Free to read 0 / 2 Behind a paywall — scores zero
Points 54 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 54 of the 96 points we could judge it on is 56 out of 100.
Total 56 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

7 studies in the alzhub library list this one in their references.

Related studies in Prevention and risk

Also tagged “machine”

834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Prevention and risk

See all studies in Prevention and risk →